EGFR and lung adenocarcinoma: The comparison was carried out by selecting an EGFR-mutant lung adenocarcinoma patient with known drug-resistance mechanisms to EGFR inhibitors via MET amplifications from the TCGA cohort (NSCLC, TCGA-38-4629).